AP9901659A0 - Quinoline-2-carboxylic acid derivatives and its use as excitatory amino acids antagonist. - Google Patents

Quinoline-2-carboxylic acid derivatives and its use as excitatory amino acids antagonist.

Info

Publication number
AP9901659A0
AP9901659A0 APAP/P/1999/001659A AP9901659A AP9901659A0 AP 9901659 A0 AP9901659 A0 AP 9901659A0 AP 9901659 A AP9901659 A AP 9901659A AP 9901659 A0 AP9901659 A0 AP 9901659A0
Authority
AP
ARIPO
Prior art keywords
antagonist
carboxylic acid
amino acids
quinoline
excitatory amino
Prior art date
Application number
APAP/P/1999/001659A
Inventor
Giuseppe Alvaro
Barbara Bertani
Fabio Romano Di
Original Assignee
Glaxo Wellcome Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome Spa filed Critical Glaxo Wellcome Spa
Publication of AP9901659A0 publication Critical patent/AP9901659A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

The (+)enantiomer of e 4-(4-acetylamino-phenylcarbamoylmethylene)-5,7-dichloro-1,2,3,4-tetrahydro quinoline 2-carboxylic acid and salt thereof which are antagonist of excitatory amino acids, to processes for their preparation, to pharmaceutical compositions containing them, and to their use in medicine.
APAP/P/1999/001659A 1997-03-26 1998-03-24 Quinoline-2-carboxylic acid derivatives and its use as excitatory amino acids antagonist. AP9901659A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9706294.7A GB9706294D0 (en) 1997-03-26 1997-03-26 Heterocyclic compound
PCT/EP1998/001700 WO1998042673A1 (en) 1997-03-26 1998-03-24 Quinoline-2-carboxylic acid derivative and its use as excitatory amino acids antagonist

Publications (1)

Publication Number Publication Date
AP9901659A0 true AP9901659A0 (en) 1999-09-30

Family

ID=10809909

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1999/001659A AP9901659A0 (en) 1997-03-26 1998-03-24 Quinoline-2-carboxylic acid derivatives and its use as excitatory amino acids antagonist.

Country Status (20)

Country Link
EP (1) EP0971896A1 (en)
JP (1) JP2001518901A (en)
KR (1) KR20010005567A (en)
CN (1) CN1257482A (en)
AP (1) AP9901659A0 (en)
AU (1) AU731394B2 (en)
BR (1) BR9808424A (en)
CA (1) CA2284710A1 (en)
EA (1) EA199900755A1 (en)
GB (1) GB9706294D0 (en)
HU (1) HUP0001661A3 (en)
ID (1) ID24306A (en)
IL (1) IL131919A0 (en)
IS (1) IS5186A (en)
NO (1) NO994679L (en)
NZ (1) NZ337793A (en)
PL (1) PL335865A1 (en)
TR (1) TR199902315T2 (en)
WO (1) WO1998042673A1 (en)
YU (1) YU47699A (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9917822D0 (en) * 1999-07-29 1999-09-29 Imperial College Nmda antagonist
DE10132725A1 (en) 2001-07-05 2006-08-03 Grünenthal GmbH Substituted γ-lactone compounds
DE10137487A1 (en) * 2001-08-03 2003-03-27 Gruenenthal Gmbh Substituted 5,6,6a, 11b-tetrahydro-7-oxa-6-aza-benzo [c] fluorene-6-carboxylic acid derivatives
DE10306202A1 (en) 2003-02-13 2004-08-26 Grünenthal GmbH 2-(hetero)aryl-2-(N-((hetero)aryl)-amino)-acetic acid derivatives useful e.g. for treating anxiety, inflammation, allergy, depression, diarrhea or especially pain is NMDA antagonist
JP4360891B2 (en) 2003-12-09 2009-11-11 アルパイン株式会社 Electronic device having broadcast receiving function and display method of electronic program guide in the device
RU2451014C2 (en) * 2005-07-22 2012-05-20 Мотида Фармасьютикал Ко., Лтд. Novel heterocyclidene acetamide derivative
NZ565080A (en) 2005-07-22 2011-03-31 Mochida Pharm Co Ltd Novel heterocyclidene acetamide derivative
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
MX393950B (en) 2017-06-12 2025-03-24 Glytech Llc COMPOSITION AND METHOD FOR THE TREATMENT OF DEPRESSION AND PSYCHOSIS IN HUMANS

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0386839B1 (en) * 1989-03-08 1997-01-15 Merck Sharp & Dohme Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
PL186781B1 (en) * 1995-09-29 2004-02-27 Glaxo Wellcome Spa Tetraguinolines as nmda antagonists
GB9617305D0 (en) * 1996-08-17 1996-09-25 Glaxo Wellcome Spa Heterocyclic compounds

Also Published As

Publication number Publication date
BR9808424A (en) 2000-05-23
NO994679L (en) 1999-11-24
EA199900755A1 (en) 2000-08-28
WO1998042673A1 (en) 1998-10-01
JP2001518901A (en) 2001-10-16
NZ337793A (en) 2001-02-23
CN1257482A (en) 2000-06-21
NO994679D0 (en) 1999-09-24
ID24306A (en) 2000-07-13
AU7209498A (en) 1998-10-20
HUP0001661A2 (en) 2000-09-28
EP0971896A1 (en) 2000-01-19
AU731394B2 (en) 2001-03-29
GB9706294D0 (en) 1997-05-14
TR199902315T2 (en) 2000-05-22
YU47699A (en) 2001-12-26
KR20010005567A (en) 2001-01-15
IL131919A0 (en) 2001-03-19
HUP0001661A3 (en) 2001-12-28
CA2284710A1 (en) 1998-10-01
IS5186A (en) 1999-09-17
PL335865A1 (en) 2000-05-22

Similar Documents

Publication Publication Date Title
AU2003269327A1 (en) Tetrahydroquinoline derivatives as crth2 antagonists
TR199900049T2 (en) Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors.
EP0394905A3 (en) Excitatory amino acid antagonists
ATE377597T1 (en) ANILINOQUINAZOLINES AS PROTEIN TYROSINE KINASE INHIBITORS
HUP0100941A2 (en) Quinoline, quinazoline and pyrido-pyrimidine derivatives and pharmaceutical compositions thereof
HUP0004490A3 (en) Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threoning kinase inhibitors and pharmaceutical compositions containing them
IL90435A0 (en) 4-(quinolin-2-yl-methoxy)phenylacetic acid derivatives,their preparation and pharmaceutical compositions containing them
NO20003698D0 (en) Oral compositions
NZ504017A (en) Preparation of gatifloxacin and disodium edetate
AP9901435A0 (en) Bicycle heteroaromatic compounds as protein tyrosine kinase inhibitors.
HUP0105133A3 (en) Quinoline derivatives and quinazoline derivatives, pharmaceutical compositions containing them and their use
TR199801861T2 (en) Pharmaceutically useful compositions.
RU95111308A (en) Derivatives of 2-amino-4-phenyl-4-oxobutyric acid, methods of synthesis, pharmaceutical composition
AP9901659A0 (en) Quinoline-2-carboxylic acid derivatives and its use as excitatory amino acids antagonist.
HUP9903492A3 (en) Quinoline derivatives as type iv phosphodiesterase inhibitors, process for their preparation, pharmaceutical compositions containing the same and their use
HUP0301080A3 (en) Substituted 1,2,3,4-tetrahydroquinoline-2-carboxylic acid derivatives, process for their preparation and pharmaceutical compositions containing them
TR199800531T1 (en) Tetrahydroquinolines as NMDA antagonists.
BR9811954A (en) 3-aryl-succinamido-hydroxamic acids, processes for their production and pharmaceutical preparations containing these substances
TNSN00240A1 (en) Heterocyclic derivatives
EP1337270A4 (en) Long-acting cytokine derivatives and pharmaceutical compositions comprising them
NO20020914D0 (en) Alkoxy-substituted benzimidazole compounds, preparations containing them and their applications
BG104452A (en) New derivatives of the methylenebisphosphonic acid
BG106329A (en) Taste masking of oral quinolone liquid preparations using ion exchange resins
SE9803107D0 (en) Novel Compunds
IL160160A0 (en) SUBSTITUTED 5,6,6a, 11b-TETRAHYDRO-7-OXA-5-AZA-BENZO[c]FLUORENE-6-CARBOXYLIC ACID DERIVATIVES SERVING AS NMDA ANTAGONISTS